Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis

Experimental Hematology

Volumn 42, Issue 5, 2014, Pages 369-379.e3

  Uchida, Tomoyuki ^a   Kitaura, Jiro ^a   Nakahara, Fumio ^a   Togami, Katsuhiro ^a   Inoue, Daichi ^a   Maehara, Akie ^a   Nishimura, Koutarou ^a   Kawabata, Kimihito C ^a   Doki, Noriko ^a,b   Kakihana, Kazuhiko ^b   Yoshioka, Kosuke ^b   Izawa, Kumi ^a   Oki, Toshihiko ^a   Sada, Akiko ^c   Harada, Yuka ^d,e   Ohashi, Kazuteru ^b   Katayama, Yoshio ^c   Matsui, Toshimitsu ^c   Harada, Hironori ^d,e   Kitamura, Toshio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIP1 LIKE1 PROTEIN; IMATINIB; INTERLEUKIN 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PONATINIB; TRANSCRIPTION FACTOR HES 1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; EOSINOPHILIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; UPREGULATION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZAMIDES; BLAST CRISIS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED BALB C; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION, MISSENSE; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 84901027095     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.01.009     Document Type: Article

References (46)

1. Kageyama R., Nakanishi S. Helix-loop-helix factors in growth and differentiation of the vertebrate nervous system. Curr Opin Genet Dev 1997, 7:659-665.
2. Nakahara F., Sakata-Yanagimoto M., Komeno Y., et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 2010, 115:2872-2881.
3. Kunisato A., Chiba S., Nakagami-Yamaguchi E., et al. HES-1 preserves purified hematopoietic stem cells exvivo and accumulates side population cells invivo. Blood 2003, 101:1777-1783.
4. Johnson J.E., Birren S.J., Anderson D.J. Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors. Nature 1990, 346:858-861.
5. Ito T., Kwon H.Y., Zimdahl B., et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010, 466:765-768.
6. Jarriault S., Brou C., Logeat F., Schroeter E.H., Kopan R., Israel A. Signalling downstream of activated mammalian Notch. Nature 1995, 377:355-358.
7. Espinosa L., Cathelin S., D'Altri T., et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010, 18:268-281.
8. Kannan S., Sutphin R.M., Hall M.G., et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 2013, 210:321-337.
9. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
10. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22:14-22.
11. Valent P., Gleich G.J., Reiter A., et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012, 5:157-176.
12. Gotlib J., Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008, 22:1999-2010.
13. Gotlib J., Cools J., Malone J.M., Schrier S.L., Gilliland D.G., Coutré S.E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004, 103:2879-2891.
14. Brito-Babapulle F. Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev 1997, 11:129-145.
15. Oliver J.W., Deol I., Morgan D.L., Tonk V.S. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 1998, 107:111-117.
16. Sada A., Katayama Y., Yamamoto K., et al. A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12. Ann Hematol 2007, 86:855-863.
17. Gilliland D.G. Hematologic malignancies. Curr Opin Hematol 2001, 8:189-191.
18. Buitenhuis M., Verhagen L.P., Cools J., Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007, 67:3759-3766.
19. Demoulin J.B., Montano-Almendras C.P. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res 2012, 2:44-56.
20. Yamada Y., Cancelas J.A., Rothenberg M.E. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia. Int Arch Allergy Immunol 2009, 149(Suppl 1):102-107.
21. Hogan S.P. Recent advances in eosinophil biology. Int Arch Allergy Immunol 2007, 143(Suppl 1):3-14.
22. Fukushima K., Matsumura I., Ezoe S., et al. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 2009, 284:7719-7732.
23. Akashi K., Traver D., Miyamoto T., Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000, 404:193-197.
24. Iwasaki H., Mizuno S., Mayfield R., et al. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005, 201:1891-1897.
25. Mori Y., Iwasaki H., Kohno K., et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med 2009, 206:183-193.
26. Uhm T.G., Kim B.S., Chung I.Y. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 2012, 4:68-79.
27. Lee J.J., Jacobsen E.A., Ochkur S.I., et al. Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red.". J Allergy Clin Immunol 2012, 130:572-584.
28. Dent L.A., Strath M., Mellor A.L., Sanderson C.J. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990, 172:1425-1431.
29. Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
30. Yamada Y., Rothenberg M.E., Lee A.W., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006, 107:4071-4079.
31. Stover E.H., Chen J., Lee B.H., et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha invitro and invivo. Blood 2005, 106:3206-3213.
32. Metzgeroth G., Erben P., Martin H., et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012, 26:162-164.
33. Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
34. Lierman E., Smits S., Cools J., Dewaele B., Debiec-Rychter M., Vandenberghe P. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia 2012, 26:1693-1695.
35. O'Hare T., Shakespeare W.C., Zhu X., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
36. Cortes J.E., Kantarjian H., Shah N.P., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
37. Ren M., Qin H., Ren R., Cowell J.K. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia 2013, 27:32-40.
38. Kagiyama Y., Kitaura J., Togami K., et al. Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice. Int J Hematol 2012, 96:638-648.
39. Watanabe-Okochi N., Kitaura J., Ono R., et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008, 111:4297-4308.
40. Kato N., Kitaura J., Doki N., et al. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood 2011, 117:221-233.
41. Elling C., Erben P., Walz C., et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011, 117:2935-2943.
42. Morita S., Kojima T., Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000, 7:1063-1066.
43. Kitamura T., Koshino Y., Shibata F., et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003, 31:1007-1014.
44. Dyer K.D., Moser J.M., Czapiga M., Siegel S.J., Percopo C.M., Rosenberg H.F. Functionally competent eosinophils differentiated exvivo in high purity from normal mouse bone marrow. J Immunol 2008, 181:4004-4009.
45. Capovilla M., Cayuela J.M., Bilhou-Nabera C., et al. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy. Eur J Haematol 2008, 80:81-86.
46. Metzgeroth G., Walz C., Score J., et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, 21:1183-1188.